Clinical insights into pharmacogenetics and schizophrenia, part 2.
Kane
John M
JM
Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.
Perlis
Roy H
RH
Malhotra
Anil K
AK
D001577:Benzophenones / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000235:genetics; D002394:Catechol O-Methyltransferase / Q000235:genetics; D065098:Catechol O-Methyltransferase Inhibitors; D003072:Cognition Disorders / Q000453:epidemiology; D015897:Comorbidity; D003937:Diagnosis, Differential; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D015870:Gene Expression / Q000235:genetics; D005838:Genotype; D006801:Humans; D009596:Nitrophenols / Q000494:pharmacology / Q000627:therapeutic use*; D010597:Pharmacogenetics; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D013685:Telecommunications; D000077867:Tolcapone
D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D004791:Enzyme Inhibitors; D009596:Nitrophenols; D000077867:Tolcapone; D002394:Catechol O-Methyltransferase